Clinical trials: Colorectal Tumor
Colorectal Cancer, Colorectal Adenoma
Molecular Imaging of Epidermal Growth Factor Receptor in Colorectal Neoplasia Using Confocal Laser Endomicroscopy
The study aims to: 1. Achieve molecular imaging of EGFR in patients with colorectal neoplasia in vivo using confocal laser endomicroscopy. 2.
- Trial name
- NCT01372189
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong University
Colorectal Neoplasms
Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment
To determine the response rate in patients with metastatic colorectal cancer who failed treatment with a 5-Fluorouracil/Leucovorin regimen and up to one other chemotherapeutic regimen (not including adjuvant chemotherapy).
- Trial name
- NCT00078468
- Testing
- PELITREXOL/AG-2037
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Pfizer
Colorectal Polyps
Metatranscriptomic Markers of Colonic Neoplasia
This study is a collaboration between Viome Life Sciences and Scripps Research Institute to develop and validate a noninvasive molecular diagnostic test for the detection of colorectal polyps.
- Trial name
- NCT07786818
- Testing
- This is an observational study that has no interventions
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Viome
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Phase I/II trial to study the effectiveness of combining SU5416 and irinotecan in treating patients who have advanced colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005818
- Testing
- irinotecan hydrochloride, semaxanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01390818
- Testing
- MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono
Anal Cancer
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00324415
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- AIDS Malignancy Consortium
Colorectal Cancer
CRC Post-surgical Assessment and Recurrence Monitoring
The surgical therapeutic effect of stage II-IV CRC patients will be assessed by the plasma mSEPT9 assay, and patients will be followed up by the same assay for recurrence monitoring.
- Trial name
- NCT03334890
- Testing
- plasma mSEPT9 level
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- BioChain (Beijing) Science and Technology, Inc.
Metastases
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM…
- Trial name
- NCT05195710
- Testing
- Yttrium-90 (Y-90) resin microspheres
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Risk for Colorectal Cancer
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
The purpose of this study is to evaluate the immune response to MUC1 - poly-ICLC vaccine, an investigational or study vaccine. The MUC1 - poly-ICLC vaccine is being tested in persons with a history of advanced adenomatous polyps…
- Trial name
- NCT00773097
- Testing
- MUC1 - Poly ICLC
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Robert Schoen
Colorectal Cancer
"High Levels of EMT-TFs for the Diagnosis of Colorectal Cancer (CRC)"
The present study is aimed at detecting and measuring mRNA levels of genes involved in epithelial to mesenchymal transition (EMT) in biological samples, i.e.
- Trial name
- NCT04323813
- Testing
- Liquid biopsy
- Where
- Italy
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Rectal Neoplasms, Rectal Cancer
Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer
Watch-and-wait strategy in rectal cancer is gaining momentum. There is a large variability in reporting the proportion of patients achieving clinical complete response (cCR) after routinely delivered preoperative…
- Trial name
- NCT04095468
- Testing
- Preoperative Radio(Chemo)Therapy
- Where
- 7 sites in Poland
- Volunteers
- 215 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Metastatic Breast Cancer or Metastatic Colorectal Cancer
A Bioequivalence Study of Capecitabine Tablets
1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG) 2.
- Trial name
- NCT01846650
- Testing
- Capecitabine tablets, XELODA
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Peritoneal Diseases
ERAS® Guidelines Validation of CRS With or Without HIPEC
Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative…
- Trial name
- NCT05185791
- Testing
- Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 288 people
- Sponsor
- Hospices Civils de Lyon
Rectal Cancer, Sigmoid Cancer
Adaptive Anastomosis for Anterior Resection in Sigmoid and Proximal Rectal Cancer or Premalignant Lesions
Background: Anastomotic leakage (AL) after colorectal surgery remains a significant challenge, associated with increased morbidity, mortality, poor oncological outcomes, and reduced quality of life.
- Conditions
- Rectal Cancer, Sigmoid Cancer, Premalignant Lesion, Colorectal Cancer
- Trial name
- ADAPT (NCT07056374)
- Testing
- C-REX RectoAid Cath
- Where
- Netherlands
- Volunteers
- 165 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Cancer (Diagnosis), Anal Cancer
Mind-Body Sexual Well-Being Program for Female GI Cancer Survivors
This record describes two distinct study phases: 1) A small open pilot trial including up to 10 participants, intended to generate descriptive feedback on regarding perceived benefits and areas for improvement for a group-based…
- Conditions
- Colorectal Cancer (Diagnosis), Anal Cancer, Sexual Dysfunction Female
- Trial name
- NCT07795801
- Testing
- Mind-Body Group Intervention, Enhanced Usual Care Control (EUCC)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Rectal Cancer
A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab
Primary Objectives To estimate the pathological complete response rate following neoadjuvant radiotherapy with concurrent capecitabine and oxaliplatin, with or without cetuximab based on the KRAS mutation status in rectal cancer.
- Trial name
- NCT00795301
- Testing
- Capecitabine, Cetuximab, Oxaliplatin
- Where
- Singapore
- Volunteers
- 74 people
- Sponsor
- National University Hospital, Singapore
Cancer Colorectal
Evaluation of Letters Promoting Colorectal Cancer Testing
In this evaluation, 4 different versions of letters are being sent with mailers promoting colorectal cancer screening with an at-home test.
- Trial name
- NCT04548765
- Testing
- Letter, Loss Frame and Fear Appeals, Transparency
- Where
- United States
- Volunteers
- 14,644 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
Rectal Cancer
Quality of Life and Psychosocial Status of Young-onset Patients With Rectal Cancer
Colorectal cancer is one of the leading cancers worldwide. Although the majority of CRC cases are typically diagnosed in individuals older than 50 years of age, recent international studies have highlighted the importance of…
- Trial name
- NCT06216834
- Testing
- No intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shandong Provincial Hospital
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Total/Subtotal Colectomy in Ovarian Cancer
The purpose of this study is to evaluate the safety and one year disease-free survival of total or subtotal colectomy and proctocolectomy in stage IIIc and stage IV epithelial ovarian, fallopian tube, and primary peritoneal…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Secondary Malignant Neoplasm of Large Intestine
- Trial name
- NCT02595021
- Testing
- Total or Subtotal Colectomy, Other Bowel Resection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Malignant Rectal Neoplasm, Recurrent Tumor
A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer
The hypothesis is that intraoperative radiotherapy for locally advanced or recurrent rectal cancer improve outcomes without causing significant side effects.
- Trial name
- NCT01493206
- Testing
- intraoperative radiotherapy
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.